ETON Eton Pharmaceuticals, Inc.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
29.05
P/S
10.27
EV/EBITDA
155.37
DCF Value
$-41.59
FCF Yield
1.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
54.8%
Operating Margin
2.3%
Net Margin
-1.7%
ROE
-5.7%
ROA
-1.5%
ROIC
3.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $24.3M | $1.6M | $— |
| Q4 null | $21.3M | $1.5M | $— |
| FY null | $80.0M | $-4.6M | $— |
| Q3 null | $22.5M | $-1.9M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$57.00
Target (Median)
$57.00
Target Range
$57.00 - $57.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.82
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.